Clinical trial
An Observational Study of the Safety and Effectiveness of Galantamine in the…
NCT00299676 · Janssen-Cilag Pty Ltd, Industry · Completed
Key facts
| NCT number | NCT00299676 |
|---|---|
| Title | An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period |
| Official title | An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period |
| Lead sponsor | Janssen-Cilag Pty Ltd, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Alzheimer Disease, Dementia, Galantamine |
| Intervention type | Drug |
| Interventions | Galantamine (Reminyl) |
| Enrollment | 61 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Mar 7, 2006 |
| Last update posted | May 23, 2014 |
| Countries | Australia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: